CN106905281A - 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 - Google Patents
厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 Download PDFInfo
- Publication number
- CN106905281A CN106905281A CN201710099660.3A CN201710099660A CN106905281A CN 106905281 A CN106905281 A CN 106905281A CN 201710099660 A CN201710099660 A CN 201710099660A CN 106905281 A CN106905281 A CN 106905281A
- Authority
- CN
- China
- Prior art keywords
- compound
- acetyl
- compounds
- application
- precipice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 flavone compound Chemical class 0.000 title claims abstract description 13
- 229930003944 flavone Natural products 0.000 title claims abstract description 9
- 235000011949 flavones Nutrition 0.000 title claims abstract description 9
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims abstract description 8
- 244000046052 Phaseolus vulgaris Species 0.000 title claims abstract description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 241000345998 Calamus manan Species 0.000 title claims abstract description 7
- 235000012950 rattan cane Nutrition 0.000 title claims abstract description 7
- 102100032404 Cholinesterase Human genes 0.000 title abstract description 6
- 101710083761 Cholinesterase Proteins 0.000 title abstract description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 title abstract description 6
- 108010013043 Acetylesterase Proteins 0.000 title abstract description 4
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 6
- 208000026139 Memory disease Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 11
- OBIUGMGQVQMVSK-UHFFFAOYSA-N barbigerone Chemical compound C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=CC=C2C1=O OBIUGMGQVQMVSK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 4
- 235000008696 isoflavones Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- XEVCTBKORYCFCZ-UXBLZVDNSA-N 4-Methoxylonchocarpin Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)C1=CC=C(OC(C)(C)C=C2)C2=C1O XEVCTBKORYCFCZ-UXBLZVDNSA-N 0.000 claims description 3
- XFUPKPIVCZRLSJ-UHFFFAOYSA-N 4-methoxylonchocarpin Natural products COC1CC(C)(C)Oc2ccc(C(=O)C=Cc3ccccc3)c(O)c12 XFUPKPIVCZRLSJ-UHFFFAOYSA-N 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims description 3
- 229940126214 compound 3 Drugs 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003390 Chinese drug Substances 0.000 claims 1
- 241001529246 Platymiscium Species 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 235000021374 legumes Nutrition 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100033639 Acetylcholinesterase Human genes 0.000 description 9
- 108010022752 Acetylcholinesterase Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000003914 Cholinesterases Human genes 0.000 description 4
- 108090000322 Cholinesterases Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 3
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229960003980 galantamine Drugs 0.000 description 3
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940124596 AChE inhibitor Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000521581 Millettia Species 0.000 description 2
- 241001639332 Millettia pachycarpa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241001090156 Huperzia serrata Species 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940021260 by ache Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- JUVIOZPCNVVQFO-HBGVWJBISA-N rotenone Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域，具体涉及从豆科植物厚果崖豆藤中分离得到的具有抑制乙酰和丁酰胆碱酯酶活性的黄酮类化合物及其可药用盐，以及含有这些化合物的药物组合物。本发明的三个黄酮类化合物对乙酰和丁酰胆碱酯酶具有显著的抑制作用，显示出在预防和治疗学习记忆障碍和老年性痴呆疾病中的独特优势。
Description
技术领域
本发明涉及医药技术领域。具体而言，本发明涉及从豆科植物厚果崖豆藤中分离得到的3种具有较强乙酰和丁酰胆碱酯酶抑制活性的黄酮类化合物及其可药用盐，以及含有这些化合物的药物组合物。可以预期其用于学习记忆障碍和老年性痴呆症的预防和治疗。
背景技术
阿尔茨海默病（Alzheimer's disease，AD）是一种渐进性神经退化性失调症，临床表现为认知和记忆功能不断恶化，日常生活能力进行性减退，并有各种神经精神症状和行为障碍。该病多为大脑原发性疾病，起病缓慢，病程呈进行性，多有家族史，是老年人群中引起痴呆的最常见的疾病。AD最显著的神经病理组织学特征是老年斑、淀粉状蛋白沉积物和神经纤维缠结，主要发生在前脑基底、海马组织和大脑皮层。
关于AD发病机制，目前有多种不同的假说，其中中枢胆碱能神经功能失调被认为是最为重要的一种。乙酰胆碱（acetylcholine，ACh）为促进学习记忆的神经递质，其在脑内被两种胆碱酯酶水解，即乙酰胆碱酯酶（Acetylcholinesterase，AChE）和丁酰胆碱酯酶（Butyrveholinesterase，BuChE）。胆碱酯酶抑制剂能延缓乙酰胆碱的水解，因此胆碱酯酶抑制剂能够提高AD患者乙酰胆碱在突触间隙的含量而产生疗效，是目前惟一被普遍认可的药物治疗手段。
目前临床应用的大部分胆碱酯酶抑制剂都是选择性的AChE抑制剂，如他克林（tacrine）、加兰他敏（galanthamine）、多奈哌齐（donepezil）、利伐司替明（rivastigmine）等。我国学者从蕨类植物蛇足石杉中发现并开发的AChE抑制剂石杉碱甲（huperzine A）也显示了良好的临床应用前景。但因其外周副作用较大，长期治疗效果不理想。Mesulam等研究发现，尽管脑内AChE较BuChE浓度高许多，但当AD患者脑中AChE活性下降时，BuChE的活性却逐渐增加，这充分表明当AChE被AChE抑制剂所抑制时，BuChE起到一定补偿作用。此外BuChE在晚期AD病人大脑中的含量很高，其在晚期AD患者脑中乙酰胆碱的水解过程中起到更为突出的作用。故建议开发AChE- BuChE双重抑制剂或选择性BuChE抑制剂。
厚果崖豆藤Millettia pachycarpa为豆科崖豆藤属植物，其种子味苦，辛，有毒，具有杀虫、攻毒和止痛的功效，主治疥癣疮癞、痧气腹痛和小儿疳积，分布于我国的浙江、四川、江西、湖南、广东、广西、贵州、云南、福建等地，为广西和贵州部分地区民间用药材。对其化学成分的研究表明，该植物中次生代谢产物主要为结构新颖的黄酮、异黄酮、二氢黄酮、查耳酮和鱼藤酮类化合物。并且其中的部分异黄酮类化合物具有较好的抗雌性激素样作用、细胞毒和诱导肿瘤细胞凋亡的活性，但是有关该植物和分离化合物的胆碱酯酶抑制活性及其在抗老年痴呆疾病中的应用尚未见报告。
发明内容：
本发明的目的是提供了一种从豆科植物厚果崖豆藤中得到有效抑制乙酰及丁酰胆碱酯酶单体化合物的方法和应用。这3个黄酮类化合物均具有明显的乙酰胆碱酯酶和丁酰胆碱酯酶抑制作用，显示出在预防和治疗学习记忆障碍和老年痴呆疾病中的独特优势。
本发明的再一目的是提供了含有本发明的化合物和制药学上可用的载体的药物组合物。
本发明的又一目的是提供了将本发明化合物用于制备预防和治疗学习记忆障碍和老年痴呆药物及与上述疾病有关的医药或保健品用途。
本发明的化合物结构式如下所示：
本发明的3个黄酮类化合物，来自豆科植物厚果鸡血藤的根、茎、叶、皮和种子中，经过提取、分离、纯化得到。也可通过半合成或全合成得到。
本发明的化合物具有较高的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性，进一步的实验结果表明本发明的化合物对两种胆碱酯酶具有双重抑制活性或选择性抑制活性。
本发明还涉及以本发明化合物作为活性成分的药物组合物。该药物组合物可根据本领域公知的方法进行制备。通过将本发明化合物与一种或多种药学上可接受的固体或液体赋形物和/或辅剂结合，制成适于人使用的任何剂型。本发明化合物在其药物组合物中的含量通常为0.01-95重量%。
本发明化合物或含有它的药物组合物可以单位剂量形式给药，给药途径包括口服、静脉注射、肌肉注射、皮下注鼻腔、口腔黏膜、呼吸道、皮肤、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂（包括真溶液和胶体溶液）、乳剂（包括O/W、W/O型和复乳）、混悬剂、注射剂（包括水针剂、粉针剂和输液）、滴鼻剂等；固体剂型可以是片剂（包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片）、胶囊剂（包括硬胶囊、软胶囊和肠溶胶囊）、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气（粉）雾剂、喷雾剂等；半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明化合物可以制成普通制剂、也可以制成缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
为了将本发明化合物制成片剂，可以广泛使用本领域公知的各种赋形剂，包括稀释剂、粘合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂是以淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、磷酸氢钙、碳酸钙等；润湿剂可以是水、乙醇、异丙醇等、粘合剂可以是淀粉浆、糊精、糖浆、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等；崩解剂可以是淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羟甲基淀粉钠、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等；润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片，例如糖包衣片、薄膜包衣片、肠溶包衣片或双层片和多层片。
为了将本发明化合物制成胶囊剂，可以将本发明化合物与稀释剂、助流剂混合，将混合物直接置于硬胶囊或软胶囊中。也可以将本发明化合物先与稀释剂、粘合剂、润湿剂、崩解剂制成颗粒或微丸，再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各种稀释剂、黏合剂、润湿剂、崩解剂和助流剂等可用于制备本发明化合物的胶囊剂。
为将本发明化合物制备成注射剂，可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH调节剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等；pH调节剂可以是磷酸盐、醋酸盐、盐酸盐、氢氧化钠等；渗透压调节剂可以是氯化钠、甘露醇、葡萄糖磷酸盐、醋酸盐等。如制备冻干粉针剂，还可以加入甘露醇、葡萄糖等作为支撑剂。
此外，如需要也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其他添加剂。
为达到用药目的，增强治疗效果，本发明的药物或药物组合物可用任何公知的给药方法给药。
本发明的化合物或组合物可单独服用，或与其它治疗药物或对症药物合并使用。当本发明的化合物与其它治疗药物存在协同作用时，应根据实际情况调整它的剂量。
具体实施例：
下面结合具体实施例对本发明作进一步阐述，但不限制本发明。
实施例1：本发明3个化合物的提取、分离、纯化的方法：
（1）取厚果鸡血藤种子4.5kg，粉碎后置于热回流装置中，用95%的乙醇浸没药材，用电热套加热回流提取，每次3小时，提取3次。
（2）将乙醇提取液真空浓缩，回收乙醇，得到乙醇浓缩液。
（3）用适量的水稀释乙醇浓缩液，得到的混悬液用石油醚进行萃取。萃取采取少量多次的原则，第一次采用水溶液一半体积的石油醚，进行萃取，以后逐步减少石油醚用量，直到石油醚层颜色非常浅为止，萃取过程中的乳化层归于水层。
（4）上层为石油醚层，将石油醚层真空浓缩回收石油醚后得到石油醚浸膏。
（5）下层为水层，水层同法用乙酸乙酯萃取，萃取过程中的乳化层归于水层。
（6）上层为乙酸乙酯层，乙酸乙酯层真空浓缩回收乙酸乙酯后得到乙酸乙酯浸膏。
（7）下层为水层，水层同法用水饱和的正丁醇萃取，萃取过程中的乳化层归于正丁醇层。
（8）上层为正丁醇层，正丁醇层真空浓缩回收正丁醇后得到正丁醇浸膏。
（9）乙酸乙酯浸膏137 g进行硅胶柱层析（8 cm柱子）分离，用石油醚-乙酸乙酯混合溶液进行梯度洗脱，将收集到的流分按照TLC检测结果、用显色剂显色后的颜色以及放置后析出沉淀等性质进行合并浓缩，得到6个流份（流份A~F）。
（10）流份B 4 g，用硅胶柱分离（2.5 cm柱子）。用石油醚-乙酸乙酯的混和溶液梯度洗脱（从10∶1，8:1到6∶1，体积比，每个梯度400 mL）。其中流份B-3～11中有橙色针晶析出，抽滤后重结晶得化合物1。
化合物1为4-methoxylonchocarpin，其结构鉴定如下：
橙色针晶，1H-NMR (400 MHz, CDCl3):δ13.79 (1H, brs, -OH), 7.85 (1H, d, J =15.2 Hz, H-α), 7.72 (1H, d, J = 9.6 Hz, H-2'), 7.61 (2H, d, J = 8.4 Hz, H-2),7.44 (1H, d, J = 15.2 Hz, H-β), 6.94 (2H, d, J = 8.8 Hz, H-3), 6.75 (1H, d, J= 10 Hz, H-4''), 6.38 (1H, d, J =9.2 Hz, H-3'), 5.59 (1H, d, J = 10 Hz, H-3''), 3.86 (3H, s, OMe), 1.47 (6H, s, 2×Me); 13C-NMR (100.0 MHz, CDCl3):δ191.9 (C-O), 161.8 (C-4'), 160.9 (C-2') , 159.9 (C-4), 144.1 (C-β), 130.5 (C-6'), 130.3 (C-2, 6), 128.1(C-2''), 127.5 (C-1), 117.8 (C-α), 115.9 (C-11''),114.4 (C-3,5), 114.1 (C-1'), 109.4 (C-3'), 108.2 (C-5'), 77.7 (C-3''), 55.4(OMe), 28.3 (2×Me)。以上光谱数据与文献(Singhal AK, Barua NC, Sharma RP, et al. Phytochemistry, 1983, 22(4): 1005-1006.)报道相符，故该化合物鉴定为4-methoxylonchocarpin。
（11）流份 D 4.8g, 用硅胶柱分离（2.5 cm柱子）。用石油醚-乙酸乙酯的混和溶液梯度洗脱（从，8:1，6:1, 4:1，2:1到 1∶1，体积比，每个梯度400 mL）。其中流份D-111～141中有白色粉末析出，抽滤后进一步纯化后得化合物2。其中流份D-216～228中有白色粉末析出，进一步纯化后得化合物3。
化合物2为barbigerone，其结构鉴定如下：
白色无定形粉末，1H-NMR (CDCl3, 400 MHz): δ 8.06 (1H, d, J = 8.4 Hz, H-4''), 7.96 (1H, s, H-2), 7.20 (1H, d, J = 2.0 Hz, H-6'), 7.04 (1H, dd, J =2.0, 8.4 Hz, H-2'), 6.92 (1H, d, J = 8.0 Hz, H-3'), 6.86 (1H, d, J = 8.8 Hz,H-5''), 6.81 (1H, d, J = 10.4 Hz, H-4''), 3.91 (6H, s, 2 × OCH3), 1.50 (6H,s, 2 × CH3). 13C-NMR (CDCl3, 100 MHz): δ175.9 (C-4), 157.3 (C-7), 152.3 (C-10), 151.9 (C-2), 149.1 (C-4'), 148.8 (C-3'), 130.3 (C-5''), 126.7 (C-5),124.7 (C-1'), 121.1 (C-6'), 118.3 (C-10), 115.3 (C-6), 114.9 (C-4''), 112.6(C-2'), 111.2 (C-5'), 109.2 (C-8), 77.7 (C-6''), 56.0 (2 × OCH3), 28.1 (2×CH3)。以上光谱数据与文献(Ye H, Chen L, Li Y, et al. Journal of ChromatographyA, 2008, 1178(1): 101-107)报道相符，故该化合物鉴定为barbigerone。
化合物3为4',5'-dimethoxy-6,6- dimethylpyrano isoflavone，其结构鉴定如下：
白色无定形粉末，1H-NMR (CDCl3, 400 MHz): δ 8.06 (1H, d, J= 8.4 Hz, H-4''),7.96 (1H, s, H-2), 7.20 (1H, d, J = 2.0 Hz, H-6'), 7.04 (1H, dd, J = 2.0, 8.4Hz, H-2'), 6.92 (1H, d, J = 8.0 Hz, H-3'), 6.86 (1H, d, J = 8.8 Hz, H-5''),6.81 (1H, d, J = 10.4 Hz, H-4''), 3.91 (6H, s, 2 × OCH3), 1.50 (6H, s, 2 ×CH3). 13C-NMR (CDCl3, 100 MHz): δ175.9 (C-4), 157.3 (C-7), 152.3 (C-10), 151.9(C-2), 149.1 (C-4'), 148.8 (C-3'), 130.3 (C-5''), 126.7 (C-5), 124.7 (C-1'),121.1 (C-6'), 118.3 (C-10), 115.3 (C-6), 114.9 (C-4''), 112.6 (C-2'), 111.2(C-5'), 109.2 (C-8), 77.7 (C-6''), 56.0 (2 × OCH3), 28.1 (2×CH3)。以上光谱数据与文献(Ye H, Chen L, Li Y, et al. Journal of Chromatography A, 2008, 1178(1): 101-107)报道相符，故该化合物鉴定为4',5'-dimethoxy-6,6- dimethylpyranoisoflavone。
实施例2 化合物对胆碱酯酶的体外抑制活性
根据文献并优化的胆碱酯酶抑制剂筛选模型，对苦檀子中分离得到的化合物进行了活性检测，发现化合物具有较高的抑制活性，其活性见表1。
表1 化合物体外抑制AChE和BChE的活性
| 化合物编号 | |||
| 1 | 17.14 ± 2.25 | 5.68 ± 0.39 | 3.03 |
| 2 | 121.60 ± 4.68 | 21.77 ± 1.06 | 5.63 |
| 3 | 131.17 ± 13.77 | 2.34 ± 0.05 | 55.98 |
| 加兰他敏 | 1.60 ± 0.02 | 13.18 ± 0.77 | 0.12 |
Claims (4)
1.具有下列结构的黄酮类化合物及其可药用盐或溶剂化物。
。
2.权利要求1所述之化合物，其名称分别为：
化合物1 为 4-methoxylonchocarpin；
化合物2 为barbigerone；
化合物3为4',5'-dimethoxy-6,6- dimethylpyrano isoflavone。
3.根据权利要求1或2所述化合物的制备途径，其主要来源于任意一种中国产的崖豆藤属植物任一部位，即可以是中国药品市场上常见的崖豆藤药材；可以是干品或鲜品；也可以是药材植物的根、茎、叶、花、种子、皮、果实，也可以是它们的混合物。
4.根据权利要求1和2所述的化合物在制备抗老年痴呆和学习记忆障碍药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710099660.3A CN106905281B (zh) | 2017-02-23 | 2017-02-23 | 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710099660.3A CN106905281B (zh) | 2017-02-23 | 2017-02-23 | 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106905281A true CN106905281A (zh) | 2017-06-30 |
| CN106905281B CN106905281B (zh) | 2019-10-08 |
Family
ID=59208576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710099660.3A Expired - Fee Related CN106905281B (zh) | 2017-02-23 | 2017-02-23 | 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106905281B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810115A (zh) * | 2019-03-21 | 2019-05-28 | 四川大学 | 异黄酮类化合物及其制备方法与应用 |
| CN112274505A (zh) * | 2020-11-13 | 2021-01-29 | 山东省分析测试中心 | 查尔酮化合物在制备治疗阿尔茨海默病药物中的应用及药物组合物 |
| CN112390774A (zh) * | 2020-11-13 | 2021-02-23 | 山东省分析测试中心 | 一种查尔酮化合物及其从刺果毛茛中的制备方法 |
| CN112402411A (zh) * | 2020-11-30 | 2021-02-26 | 山东省分析测试中心 | 查尔酮化合物在制备改善睡眠药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063769A1 (en) * | 2001-12-28 | 2006-03-23 | Yuji Ishihara | Preventives/remedies for urinary disturbance |
-
2017
- 2017-02-23 CN CN201710099660.3A patent/CN106905281B/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063769A1 (en) * | 2001-12-28 | 2006-03-23 | Yuji Ishihara | Preventives/remedies for urinary disturbance |
Non-Patent Citations (1)
| Title |
|---|
| HAOYU YE, ET AL.: "Cytotoxic and apoptotic effects of constituents from Millettia pachycarpa Benth", 《FITOTERAPIA》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810115A (zh) * | 2019-03-21 | 2019-05-28 | 四川大学 | 异黄酮类化合物及其制备方法与应用 |
| CN109810115B (zh) * | 2019-03-21 | 2020-09-11 | 四川大学 | 异黄酮类化合物及其制备方法与应用 |
| CN112274505A (zh) * | 2020-11-13 | 2021-01-29 | 山东省分析测试中心 | 查尔酮化合物在制备治疗阿尔茨海默病药物中的应用及药物组合物 |
| CN112390774A (zh) * | 2020-11-13 | 2021-02-23 | 山东省分析测试中心 | 一种查尔酮化合物及其从刺果毛茛中的制备方法 |
| CN112274505B (zh) * | 2020-11-13 | 2022-01-04 | 山东省分析测试中心 | 查尔酮化合物在制备治疗阿尔茨海默病药物中的应用及药物组合物 |
| CN112390774B (zh) * | 2020-11-13 | 2022-05-17 | 山东省分析测试中心 | 一种查尔酮化合物及其从刺果毛茛中的制备方法 |
| CN112402411A (zh) * | 2020-11-30 | 2021-02-26 | 山东省分析测试中心 | 查尔酮化合物在制备改善睡眠药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106905281B (zh) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106905281B (zh) | 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 | |
| CN1977951B (zh) | 用于防治老年性痴呆的天麻植物提取物及其制备方法 | |
| CN103059043A (zh) | 伸筋草碱a-c、其制法和其药物组合物与用途 | |
| CN102526165A (zh) | 一种红景天有效部位、其制备方法、其药物组合物及用途 | |
| WO2010133015A1 (zh) | 治疗抑郁症的药物组合物、制备方法及用途 | |
| CN103172643B (zh) | 黄皮咔唑生物碱及其制备方法和其药物组合物与用途 | |
| CN108191616A (zh) | 白及中具有选择性丁酰胆碱酯酶抑制作用的单体成分及其用途 | |
| CN106421589A (zh) | 一种降尿酸的中药有效部位及其制备方法和应用 | |
| CN103054929A (zh) | 一种红景天提取物、其药物组合物和治疗脂肪肝病的用途 | |
| CN102000127B (zh) | 蜡梅属植物抑制乙酰胆碱酯酶活性部位的制备及其应用 | |
| CN103360456A (zh) | 三萜类化合物及制备和应用 | |
| CN102178721B (zh) | 绞股蓝混悬液、提取物在制备治疗抗抑郁症药物中的应用 | |
| CN105012356B (zh) | 灵芝酸a在抗抑郁症中的用途 | |
| CN102526170A (zh) | 抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用 | |
| CN105534971B (zh) | 二苯并氧杂环庚三烯类化合物在体外筛选或制备药物中的应用 | |
| CN101613340B (zh) | 一种榛子素及其提取方法和药物用途 | |
| CN103641713A (zh) | 甘油单酯衍生物的制备方法及应用 | |
| CN103494813A (zh) | 盐酸去亚甲基小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用 | |
| CN100464760C (zh) | 苍耳子总苷提取物用于制备抗炎性反应产品的用途 | |
| CN103479623A (zh) | 香豆素类化合物双白瑞香素的新用途 | |
| CN106810495A (zh) | 吴茱萸中新喹诺酮类生物碱及其制备方法、应用和药物组合物 | |
| CN103420805A (zh) | 天麻中具有神经细胞保护活性的多聚苄类衍生物 | |
| CN101461803B (zh) | 葡萄内酯的用途 | |
| CN109512901A (zh) | 了哥王提取物及其在制备镇痛抗炎药物中的应用 | |
| CN104523819B (zh) | 一种紫穗槐提取物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191008 Termination date: 20210223 |